secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001213900-23-084938
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics reports Q3 2023 net loss of $17.5M; highlights IND clearance for briquilimab in CSU
--------------------------------------------------------------------------------

- Net loss of $17.5M ($0.16 per share); R&D expenses $14.8M; G&A expenses $4.5M.
- Cash and cash equivalents of $103.9M as of Sept 30, 2023.
- FDA cleared IND for Phase 1b/2a study of subcutaneous briquilimab in CSU; first patient expected by end of 2023.
- Stanford-sponsored Phase 1/2 study in Fanconi Anemia: all 3 patients achieved full donor engraftment.
- Appointed Thomas Wiggans as Chairperson and Herb Cross as CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023084938/0001213900-23-084938-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023084938/ea187963-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-084938

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer